Summary
- Profile Type
- Technology offer
- POD Reference
- TOTR20250106002
- Term of Validity
- 6 January 2025 - 6 January 2026
- Company's Country
- Turkey
- Type of partnership
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A biotech company founded in 2019 and based in Kayseri, Central Anatolia, is developing peptide-based therapeutic vaccines targeting viruses, bacteria, and cancer. Their platform enables the production of vaccines that are safe, stable, cost-effective, and free from pathogen contamination. The company is seeking investors to support the advancement of its vaccine pipeline and technology.
- Full Description
- Established in 2019 in Kayseri, Central Anatolia, this biotech company focuses on developing peptide-based vaccines for infectious diseases and cancer. The company’s proprietary platform allows for the large-scale production of vaccines with advantages such as pathogen-free manufacturing, safety due to the absence of nucleic acids, ease of synthesis, low production costs, and enhanced stability. Currently, the company is advancing vaccines for White Spot Virus and Mycetoma, with clinical trials to be conducted by contract research organisations in Türkiye, China, and the U.S. under Good Clinical Practice (GCP) standards. The company is seeking investors to help drive the development and commercialisation of its peptide-based vaccine platform. Interested parties are encouraged to explore potential collaboration and investment opportunities.
- Advantages and Innovations
- The company utilizes innovative peptide-based technology to develop vaccines that are safe, cost-effective, and scalable for large-scale production. These vaccines specifically target pathogens and cancer cells while minimizing risks associated with traditional vaccine platforms. With a focus on pathogen-free production and rapid adaptation to emerging health threats, the company aims to address critical public health challenges and improve health outcomes globally.
- Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
- Goal 5: Gender Equality
- IPR status
- No IPR applied
Partner Sought
- Expected Role of a Partner
-
- Peptide Synthesis: Advanced synthesis and characterization techniques.
- Vaccine Formulation: Expertise in stable formulations and adjuvant selection.
- Immunological Assays: Development of assays for efficacy and safety evaluation.
- Clinical Trials: Design and compliance with Good Clinical Practice (GCP).
- Regulatory Affairs: Knowledge of vaccine development regulations.
- Pathogen Characterization: Expertise in identifying peptide targets. - Type and Size of Partner
- Big company
- SME 11-49
- SME <=10
- Other
- SME 50 - 249
- University
- R&D Institution
- Type of partnership
- Investment agreement
Dissemination
- Technology keywords
- 06001015 - Pharmaceutical Products / Drugs
- 06001006 - Human vaccines
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- 05007007 - Other medical/health related (not elsewhere classified)
- Sector Groups Involved
- Health
- Targeted countries
- All countries